Targeted Therapies in Cholangiocarcinoma Video Perspectives

Healio spoke with Sumera I. Ilyas, MBBS, about targeted treatment options in cholangiocarcinoma.

“Prior to the era of precision medicine, which ushered in multiple targeted therapies, the systemic therapy treatment options for patients with cholangiocarcinoma were quite limited and not very effective,” Ilyas, gastroenterologist, physician-scientist and transplant hepatologist with Mayo Clinic, said. “So, the emergence of targeted therapy has, without a doubt, brought in treatment options for our patients.”

In this video series, she discussed:

• the current landscape of targeted treatment in cholangiocarcinoma;
• the subtype of patients with targetable genetic abnormalities in their tumors;
• genetic mutations and alterations in cholangiocarcinoma;
• the impact that targeted therapies have had on the management of cholangiocarcinoma;
• recent advancements and approvals in the field;
• clinical trials;
• challenges treating and managing cholangiocarcinoma during the height of the COVID-19 pandemic;
• areas of unmet need, including early diagnosis;
• the importance for research to focus on understanding the tumor landscape of cholangiocarcinoma; and
• the need for better biomarkers.

Disclosure:

Ilyas reports a consultant role with AstraZeneca.